S&P/ASX 200 Index (ASX: XJO) tech stocks are under pressure today.

In late morning trade on Monday, the S&P/ASX All Technology Index (ASX: XTX) – which also contains some smaller technology-focused companies outside of ASX 200 tech stocks – is down 0.8%.

Here’s how five of the biggest ASX tech companies are performing at this same time:

• Shares in cloud-based software solutions provider WiseTech Global Ltd (ASX: WTC) are down 1.2% at $70.15
• Shares in software-as-a-service provider Technology One Ltd (ASX: TNE) are down 0.6% at $27.04
• Shares in data centre operator NextDc Ltd (ASX: NXT) are down 2.5% at $13.17
• Shares in location-sharing software developer Life360 Inc (ASX: 360) are down 0.8% at $34.54
• Shares in accounting software provider Xero Ltd (ASX: XRO) are down 1.1% at $111.60

Why are ASX 200 tech stocks losing ground today?

Today’s sell-down has nothing to do with new company-specific negative developments from the above-mentioned stocks.

Instead, ASX 200 tech stocks are following the lead of the major United States-based tech shares lower, with the Nasdaq Composite Index (NASDAQ: .IXIC) closing down 1.7% on Friday.

The tech sector hit some turbulence amid rising investor concerns that AI-related stocks may have seen too much money flowing in too quickly. Amid the massive costs involved in developing ever-evolving AI technology, along with the data centres to support it, questions remain over the potential revenue on offer at the end of the road.

Shares in generative AI chip-making giant Nvidia Corp (NASDAQ: NVDA) fell 3.3% on Friday and are now down 15.5% from the 29 October all-time closing high.

And following last Thursday’s 10.8% drop after revealing increasing AI expenditures, shares in cloud computing software giant Oracle Corp (NYSE: ORCL) are now down 42.1% since posting its own record closing high on 22 September.

What the experts are saying

Commenting on the AI-linked tech sell-off that’s impacting ASX 200 tech stocks today, Jim Morrow, CEO of Callodine Capital Management, said (quoted by Bloomberg), “We’re in the phase of the cycle where the rubber meets the road. It’s been a good story, but we’re sort of anteing up at this point to see whether the returns on investment are going to be good.”

Eric Clark, portfolio manager at the Rational Dynamic Brands Fund, added:

If you think about how much money, it’s in the trillions now, is crowded into a small group of themes and names, when there’s the first hint of that theme even having short-term issues or just valuations get so stretched they can’t possibly continue to grow like that, they’re all leaving at once.

Louis Navellier, CEO at Navellier & Associates, noted that after the strong run to new recent record highs, some profit taking is to be expected (quoted by The Australian Financial Review).

“The AI bubble is deflating but not popping,” he said.

ASX 200 tech stocks have materially underperformed their US counterparts in 2025.

Year to date, the Nasdaq remains up 20.1% while the ASX All Tech Index is now down 10.6% this year.

The post Why are ASX 200 tech stocks like Xero shares taking a beating on Monday? appeared first on The Motley Fool Australia.

More reading

• These exciting ASX 200 growth shares could rise 60% to 100% in 2026
• 2 ASX shares to buy and hold for the next decade
• Top brokers name 3 ASX shares to buy next week
• Brokers name 3 ASX shares to buy today
• The best Australian stocks to buy today and not check again until 2035

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Nvidia, Oracle, Technology One, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended Life360, WiseTech Global, and Xero. The Motley Fool Australia has recommended Nvidia and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

While the market is on pace for a strong 2025, most of the stocks in the “Magnificent Seven” merely had good, not fantastic, years. But one Magnificent Seven stock clearly took the crown in 2025: Google parent Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL).

GOOG Year to Date Total Returns (Daily) data by YCharts.

As you can see, Alphabet’s 64% return trounced the rest of the Magnificent Seven, beating 2025’s second-best performer, Nvidia (NASDAQ: NVDA), by a whopping 33 percentage points and most of the others in the group by more than 50 points.

Here’s how Alphabet did it and why the rally may very well continue into 2026.

Alphabet entered the year as the cheapest Magnificent Seven stock and still isn’t expensive

Coming into the year, Alphabet had been a notable laggard, with its valuation reflecting considerable fear, uncertainty, and doubt in the age of generative artificial intelligence (AI). As a result, Alphabet began the year at the lowest valuation of the group. At one point, its price-to-earnings (P/E) ratio even touched the high teens — below the average valuation of the S&P 500.

Yet, as you can see, even with this year’s vast outperformance, Alphabet retains the second-lowest P/E ratio of the group at 30.6 times trailing earnings, barely beating out Meta Platforms.

GOOG PE Ratio data by YCharts. PE Ratio = price-to-earnings ratio.

Alphabet engineered a turnaround, and Buffett saw it coming

The primary concern entering the year was that AI chatbots might eventually disrupt Google Search, which is still Alphabet’s largest profit center. It’s also true that, early in the year, Google Search showed a concerning deceleration in paid clicks. Yes, there was still growth, but by the first quarter, paid click growth had fallen to just 2%, with concerns that it might eventually go negative.

However, on its second-quarter earnings, Alphabet began to prove that narrative wrong, as Search paid clicks reaccelerated to 4% growth. That might have been when Warren Buffett or his lieutenants decided to buy Alphabet stock for the Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) portfolio. Whatever the reason, the buy proved prescient, as Search paid click growth accelerated yet again in the third quarter to 7%. 

AI improvements bolstered Search and Gemini

It wasn’t just a matter of luck that Alphabet was able to reaccelerate Search paid clicks. The reacceleration of Search happened just after Google introduced AI Mode in May, giving Search users the option of a chatbot-like experience powered by Alphabet’s own homegrown large language models (LLMs). It appears the improvement, combined with 2024’s introduction of AI Overviews, caused Search users to reengage.

Of course, all of that AI infusion into Search would have been for naught if Alphabet’s AI models weren’t competitive. However, Alphabet has clearly upped its AI game over the past year. The vast improvement was confirmed by the November introduction of Gemini 3, Alphabet’s latest LLM, which rapidly climbed to the top of several industry benchmarks, beating out even the latest ChatGPT model on many important tasks.

The introduction of Gemini 3 appears to signify at least a near-term changing of the guard in the AI race, as ChatGPT had pretty much retained its first-mover advantage since introducing LLM chatbots to the world in late 2022. Subsequent to Gemini 3’s launch, OpenAI CEO Sam Altman issued a “code red” memo to OpenAI’s employees.

Alphabet can maintain its new lead in the AI race

Years ago, Alphabet had a virtual monopoly on artificial intelligence research before OpenAI was formed to challenge its industry-leading research lab. In fact, Alphabet’s researchers were the first to innovate transformer technology, which is the backbone of modern-day LLMs.

Not only does Alphabet have a longer history of deep AI research than even OpenAI, but it has also designed its own proprietary AI chips for the past decade. Alphabet trained Gemini not on expensive Nvidia chips but on its in-house-designed Tensor Processing Units, or TPUs. That’s a proprietary technology of Google and a point of differentiation.

Proprietary AI research and in-house chips have enabled Google to become a vertically integrated AI player with the most extensive collective experience in the field. And although OpenAI clearly caught Alphabet off guard when it unveiled ChatGPT three years ago, it appears that Alphabet has now caught up and surpassed OpenAI, at least for now.

Given Alphabet’s significantly greater financial resources, more years of AI research experience, and its own proprietary chips, Google may even continue to augment its new lead.

Why things could get even better for Alphabet in 2026

Not only that, but Alphabet also has several businesses it can infuse with its newfound AI leadership. For instance, many of the most reputable private AI labs conduct their research on Google Cloud, thanks to its proprietary TPU option alongside the standard GPU formats. Google’s cloud business is accelerating and could become a meaningful new profit center in the years ahead.

Additionally, Alphabet’s self-driving unit, Waymo, appears to be growing by leaps and bounds. This past spring, Waymo reached one million autonomous rides per month, and it surpassed 14 million rides in 2025 as of December — more than triple the number of rides delivered the previous year. Waymo also just began delivering autonomous rides on freeways, and Alphabet plans to expand Waymo services in 20 cities in 2026.

Autonomous robotaxis could become a significant business in a few years, and Waymo has a substantial first-mover advantage in this space. That could add still another leg to Alphabet’s burgeoning empire across Search, AI services, YouTube, Cloud, hardware, subscriptions, and other next-generation technology bets.

In other words, with the big looming fear regarding Search seemingly quelled for now, one could argue that Alphabet should be priced higher than its other Magnificent Seven peers today, rather than the second-cheapest of the bunch.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Why the best-performing “Magnificent Seven” stock of 2025 is still a buy for 2026 appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• What Warren Buffett’s latest portfolio moves say about the market
• These 2 magnificent seven AI stocks might be offering investors a once-in-a-decade buying opportunity before the New Year.
• The 3 smartest quantum computing stocks to buy with $1,000 in 2026
• Alphabet just did something it hasn’t done in 7 years. Time to buy?
• Is Gemini Enterprise a game changer for Alphabet?

Billy Duberstein and/or his clients have positions in Alphabet, Berkshire Hathaway, and Meta Platforms. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Apple, Berkshire Hathaway, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended Alphabet, Amazon, Apple, Berkshire Hathaway, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shareholders in Telix Pharmaceuticals Ltd (ASX: TLX) have had a rough year if they bought near the company’s 12-month highs, but the good news is one broker at least thinks they’ll deliver significant gains over the coming year.

RBC Capital Markets has just initiated coverage of Telix shares and has a “sector perform” rating on the company.

Strong development pipeline

The RBC analysts say that at the current share price, there’s a lot to like about the biotechnology company, which has more than one iron in the fire.

As the analysts wrote in a note to clients:

Telix is a radiopharmaceutical company that has successfully commercialised two diagnostic assets in prostate cancer and there are significant opportunities to expand indications. Telix also has a large portfolio of pipeline assets across urology, neurology, musculoskeletal and hematologic oncology that it is working to commercialise.

That’s the good news, but the RBC team said shareholders might have to wait some time for earnings and free cash flow to tick up, with the company investing in its research and development pipeline.

As the RBC team said:

While we are forecasting a record level of sales and cash receipts from FY25-FY27, we expect EBIT and free cash flow to remain broadly flat due to an increase in R&D costs to commercialise Telix’s pipeline. We anticipate Telix will only become EBIT and FCF positive in FY28.  

On the upside, RBC said Telix has a large portfolio in its development pipeline.

Telix has a large pipeline portfolio. In our view, the most promising candidates are TLX591 as its phase two data showed a significant improvement in median overall survival (OS) of 23.6 months, TLX250 given early clinical data (phase two showed 57% disease stabilisation), TLX101-CDx given its higher sensitivity and specificity, and TLX101 given its phase 2 data showed a favourable improvement in OS of 12.4 months.

Potential to expand scope

RBC said Telix was also working to expand the utility of its prostate cancer imaging agents, which would extend them for use in early diagnosis and other monitoring indications, and which could expand the addressable market in the US from 645,000 scans per year to about 1.7 million.

RBC has a price target of $17 on Telix shares, compared with the price of $13.15 on Monday. If the shares were to reach this level it would constitute a gain of 29.3%.

The company has traded as high as $31.97 over the past 12 months and as low as $13.04.

Telix was valued at $4.65 billion at the close of trade on Friday.  

The post Which drug company could pile on almost 30% in gains according to RBC Capital? appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• These exciting ASX 200 growth shares could rise 60% to 100% in 2026
• These are the 10 most shorted ASX shares
• Telix shares fall despite ‘significant milestone’
• Telix Pharmaceuticals updates investors as first patient is dosed in Phase 3 prostate cancer trial

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Coles Group Ltd (ASX: COL) and Woolworths Group Ltd (ASX: WOW) shares are both significantly underperforming the benchmark on Monday.

In morning trade today, the S&P/ASX 200 Index (ASX: XJO) is down 0.6%.

As for the ASX 200 supermarket giants, Coles shares are down 1.7% trading for $21.43 apiece. And Woolworths shares are down an even steeper 2.4%, changing hands for $28.86 each.

Atop headwinds from the sell-down in US stock markets on Friday, both ASX 200 supermarkets look to be under pressure following Treasurer Jim Chalmers’ announcement over the weekend aimed to stamp out alleged price gouging.

Here’s what’s happening.

Coles and Woolworths shares facing new margin pressure

Over the weekend, the Labor government announced its intention to implement new rules targeting excessive pricing of groceries beyond a reasonable profit margin.

“One of the best ways to ease the cost of living for Australians is to help people get fairer prices at the checkout,” Chalmers said on Sunday.

Investors may be reevaluating the outlook for Coles shares and Woolworths shares, as the two companies are the only ones currently targeted by the legislation. If they breach the rules, they could face penalties of $10 million per violation.

The ASX 200 supermarkets were clearly displeased with the new rules.

“The law is unprecedented by targeting only two Australian-owned companies,” a Woolworths spokesperson said.

ASX 200 supermarket giants respond

Both Coles and Woolworths have made confidential submissions to Treasury officials on Chalmers’ new law, which were obtained by The Australian Financial Review.

Both companies noted that the legislation could, in fact, lead to higher prices.

Commenting on the new law that could impact Woolworths shares, the company said (quoted by the AFR):

Our pricing is highly dynamic, with thousands of changes weekly in response to competitive moves and promotions. Our systems are built to execute these price changes, not to create and store a detailed legal and economic justification for each one.

We would be required, at a minimum, to employ a dedicated full-time team for the sole purpose of monitoring whether our pricing is ‘excessive’, against unclear and unknown ‘benchmarks’. In the context of there being no evidence of ‘price gouging’, this simply adds cost to the Woolworths supermarkets business and puts us at a competitive disadvantage.

And with Coles shares also potentially facing a hit from the new law, Coles noted that it could add layers of red tape to pricing fruits and veggies. According to the company:

The unnecessary excessive pricing laws are likely to act as an impediment to supermarkets locking in prices further in advance. This is because of the risk of a significant divergence emerging between a price that is agreed well in advance and the ultimate market price at time of sale.

Coles added, “For every $100 customers spend at Coles, we make around $2.43 in profit, less than 3 cents in the dollar.”

With today’s intraday moves factored in, Coles shares are up 14.6% since this time last year. Woolworths shares have dropped 5.7% over this same period.

The post Buying Coles and Woolworths shares? Here’s why the supermarkets are fuming over Chalmers’ new law appeared first on The Motley Fool Australia.

More reading

• 2 premier ASX shares for your retirement fund
• Why Coles shares are a retiree’s dream
• Woolworths shares are down 12% from their peak. Should those who don’t own them consider buying now?
• RBA watch: Sectors to target and avoid should interest rates rise – Expert
• What’s going on with the Woolworths dividend?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Woolworths Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

At the start of each week, I like to look at ASIC’s short position report to find out which shares are being targeted by short sellers.

This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn’t quite right with a company.

With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:

• Boss Energy Ltd (ASX: BOE) remains the most shorted ASX share with short interest of 23.7%. This is down week on week. There are concerns that the uranium miner’s production beyond 2026 will fall short of expectations.
• Domino’s Pizza Enterprises Ltd (ASX: DMP) has seen its short interest ease slightly to 16.9%. This pizza chain operator has been struggling in recent years and short sellers appear to believe it won’t be a quick fix.
• Guzman Y Gomez Ltd (ASX: GYG) has short interest of 13.2%, which is up week on week again. Valuation concerns are likely to be behind this. Especially given the disappointing performance of its US business, which was seen as a key driver of long term growth.
• Paladin Energy Ltd (ASX: PDN) has short interest of 13.1%, which is down slightly week on week. A number of uranium stocks are being targeted by short sellers. This could be on the belief that nuclear power adoption won’t be as great as some predict.
• IDP Education Ltd (ASX: IEL) has 12% of its shares held short, which is down week on week. This language testing and student placement company’s shares are down 60% this year after unfavourable visa changes and trading conditions weighed on its performance and outlook.
• Flight Centre Travel Group Ltd (ASX: FLT) has short interest of 11.7%, which is up slightly since last week. Short sellers continue to load up on this travel agent’s shares despite its positive start to FY 2026 and news of a key acquisition this month.
• PWR Holdings Ltd (ASX: PWH) has short interest of 11.3%, which is up week on week again. This motorsport products company has been out of form recently and warned that FY 2026 could be another transitional year.
• Polynovo Ltd (ASX: PNV) has short interest of 11.2%, which is flat since last week. This could be due to valuation concerns, with the medical device company’s shares trading on sky-high multiples.
• Telix Pharmaceuticals Ltd (ASX: TLX) has short interest of 11%, which is up week on week. This biotech company has been struggling with delays to FDA approvals this year.
• IPH Ltd (ASX: IPH) has entered the top ten with short interest of 10.9%. This intellectual property services provider has been battling weak trading conditions. Short sellers appear to believe this weakness will continue.

The post These are the 10 most shorted ASX shares appeared first on The Motley Fool Australia.

More reading

• Which drug company could pile on almost 30% in gains according to RBC Capital?
• These exciting ASX 200 growth shares could rise 60% to 100% in 2026
• Top brokers name 3 ASX shares to buy next week
• These ASX 200 shares could rise 50% to 65%
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has positions in Domino’s Pizza Enterprises. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Domino’s Pizza Enterprises, PWR Holdings, PolyNovo, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended PWR Holdings. The Motley Fool Australia has recommended Domino’s Pizza Enterprises, Flight Centre Travel Group, IPH Ltd , PolyNovo, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in gold exploration minnow Redcastle Resources Ltd (ASX: RC1) jumped more than 50% in early trade on Monday after the company announced “exceptional” gold assays from its Redcastle Reef prospect.

The company said on Monday that the first results from grade control drilling at the prospect had delivered some very high gold results, including a 1m section measuring 3650 grams per tonne of gold at a depth of 15m.

The company did caution that such high results were indicative of “nuggety” gold, which was known to occur at the prospect, and which would be typically cut to a lower value during resource estimation.

Strong grades welcomed

Other results included 7m at a grade of 527 grams per tonne of gold across 7m (including the previously reported section) and 2m at 14.58 grams per tonne of gold from a depth of 24m.

Redcastle said the results were from the first eight holes planned as part of the grade control drilling program, which was being conducted by its joint venture partner BML Ventures.

The company went on to say:

The drilling program at Redcastle Reef is planned to include approximately 12,800m on an 8m x 6m grid and designed to improve grade definition for mine planning and gold production.

Redcastle Resources Chair Ray Shaw said on Monday:

These initial grade control results from Redcastle Reef are highly encouraging, with multiple high-grade intercepts reported over meaningful widths, demonstrating the continuity and tenor of the mineralised system. It is particularly encouraging to see that … grade control drilling is supporting Redcastle’s existing mineral resource estimate (MRE) drilling results. Redcastle Reef has long been recognised for the presence of coarse gold, and these results further confirm that characteristic. Redcastle is fortunate to have access to experienced personnel with extensive expertise in managing coarse-gold mineralisation in the Eastern Goldfields over many years.

Drilling is continuing at the prospect, and new results will be reported as they come in, the company said.

Happy hunting grounds

Redcastle’s portfolio of gold exploration assets is located about 60km east-southeast of the Gwalia gold mine, the company said.

The portfolio comprises a series of contiguous tenements centrally located within a region known as the ‘golden circle’, an area delineated by multi-million-ounce gold mining operations within the highly prospective Leonora-Laverton portion of the greenstone belt of the eastern Yilgarn.

Redcastle shares traded as high as 11.5 cents on the news, up 51.3%, before settling back to be 26.3% higher at 9.6 cents.

Redcastle Resources was valued at $9.1 million at the close of trade on Friday.

The post Gold junior’s shares jump more than 50% on “exceptional” drilling results appeared first on The Motley Fool Australia.

More reading

• Which drug company could pile on almost 30% in gains according to RBC Capital?
• Buying Coles and Woolworths shares? Here’s why the supermarkets are fuming over Chalmers’ new law
• These are the 10 most shorted ASX shares
• 1 reason I will never sell Meta Platforms stock
• This ASX 200 stock is charging higher on FDA approval news

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Meta Platforms has a rare ecosystem

Meta Platforms ended the third quarter with 3.54 billion daily active users across its websites and mobile apps, an 8% year-over-year increase. The world’s population is about 8.3 billion people. If we remove all those who are too young to have an Instagram account, it may well be the case that something like half of eligible adults (or young adults) worldwide visit at least one of Meta’s websites and apps every single day. That user base is a veritable goldmine.

And the best part: Most of them are unlikely to go anywhere anytime soon, given the company’s strong network effects. Consider why people open Instagram accounts. It could be to keep up with friends and family, to become an influencer, or to promote products for their businesses, among other reasons. For each of these uses, the platform becomes even more valuable as more people join in, and for those who are already in those networks, it makes little sense to leave.

Meta Platforms’ ecosystem makes it an incredible target for advertisers. It also allows it to launch new monetization opportunities. Less than three years ago, Meta Platforms launched its X competitor, Threads — it already has 150 million daily active users. According to management, it’s on track to become the leader in its category.

Facebook Marketplace is another opportunity that fits naturally within the company’s strategy. Anyone else starting an online platform to connect buyers and sellers would have to work hard to attract an audience. For Meta Platforms, it wasn’t difficult since it already has a large one. So long as Meta Platforms’ vast ecosystem stays in place, the tech leader should find many more monetization schemes, even as advertising remains the most important.

Meta is a buy-and-forget stock

Meta Platforms’ work in AI is undoubtedly strengthening the business. For instance, AI-powered algorithms are helping it increase engagement while enhancing the return on investment marketers get from ads on its platforms. However, none of that would matter if not for the company’s existing user base. Meta still has ample growth potential over the long run, and much of the fuel for that will be its vast ecosystem. That’s why I am staying put.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post 1 reason I will never sell Meta Platforms stock appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• These 2 magnificent seven AI stocks might be offering investors a once-in-a-decade buying opportunity before the New Year.
• Meta Platforms stock jumps on Metaverse spending cuts. Here’s why the growth stock is a screaming buy before 2026
• 1 compelling reason to buy Meta hand over fist right now
• Screaming buy? This ASX ETF has returned 54% a year since 2022
• 2 artificial intelligence (AI) stocks to buy before the end of 2025

Prosper Junior Bakiny has positions in Meta Platforms. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Meta Platforms. The Motley Fool Australia has recommended Meta Platforms. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are starting the week strongly.

In morning trade, the ASX 200 stock is up 3.5% to $19.59.

Why is this ASX 200 stock rising today?

Investors have been bidding the pharmaceuticals company’s shares higher today after it received approval from regulators in the United States for a new product.

According to the release, its partner in the United States, Acadia Pharmaceuticals (NASDAQ: ACAD), has received US Food and Drug Administration (FDA) approval of Daybue STIX. It is a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and paediatric patients two years of age and older. It is a rare genetic disorder that affects the way the brain develops, impacting the ability to use muscles for eye and body movements and language.

It notes that the new powder formulation offers children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their Daybue treatment.

The ASX 200 stock advised that the approval of this new formulation was supported by the results of a bioequivalence study. This study demonstrated that both original Daybue oral solution and the new Daybue STIX powder formulation provide comparable exposure.

This confirmed bioequivalence means patients can expect the same efficacy and safety established by the oral solution formulation when using Daybue STIX.

Acadia has advised that it expects Daybue STIX to be available on a limited basis starting in the first quarter of 2026.

After which, it will be more broadly available early in the second quarter of 2026. The current oral solution formulation will remain available.

Acadia has an exclusive worldwide licence for the development and commercialisation of trofinetide (Daybue). This agreement sees Neuren receive royalties on all net sales of trofinetide and is eligible to receive additional payments on achievement of commercial and development milestones.

Neuren’s CEO, Jon Pilcher, was pleased with the news. Commenting on the approval, he said:

The Neuren team is excited about the approval of this new treatment option for Rett syndrome families and the continued investment and innovation for trofinetide by our global partner, Acadia. Caregivers can mix Daybue STIX with a variety of water-based liquids providing flexibility to modify the taste and volume of their loved-one’s dose. We look forward to seeing the impact as Daybue STIX becomes more broadly available during 2026.

The post This ASX 200 stock is charging higher on FDA approval news appeared first on The Motley Fool Australia.

More reading

• Neuren Pharmaceuticals wins DAYBUE STIX FDA approval
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The All Ordinaries Index (ASX: XAO) is down 0.6% today, but don’t blame this rocketing ASX All Ords gold share.

The surging stock in question is Gorilla Gold Mines Ltd (ASX: GG8).

Gorilla Gold shares closed on Friday trading for 47 cents. In early morning trade on Monday, shares are changing hands for 49.5 apiece, up 5.3%. The Gorilla Gold share price is now up 136% since the 12 February close, when you could have picked up shares for just 21 cents apiece.

Today’s outperformance follows news of a major mineral resource upgrade at the miner’s 100%-owned Comet Vale Gold Project, located in Western Australia.

Here’s what’s grabbing investor interest.

ASX All Ords gold share leaps on resource boost

Investors are bidding up the Gorilla Gold share price after the miner reported a 900% increase in the previously estimated mineral resource for Comet Vale to 860,000 ounces of contained gold (7.3 Mt at 3.7g/t Au).

The ASX All Ords gold shares noted that it delivered the additional ounces of gold at a discovery cost of around $25 per ounce.

The indicated component of the Comet Vale mineral resource estimate now totals 1.7 Mt at 4.1g/t Au for 220,000 ounces of gold.

Comet Vale has seen historical gold production of more than 200,000 ounces at 20g/t Au. Underground operations were running at the project until 2020.

The ASX All Ords gold share made a high-grade gold discovery at the nearby Lakeview Prospect in February 2025, with the miner noting new extensional lodes were also discovered at Cheer and Sovereign in January 2025.

Gorilla noted “clear potential” for additional increases in the gold resource base at Comet Vale. Three drill rigs are currently operating at the site.

What did management say?

Commenting on the resource upgrade helping to lift the ASX All Ords gold share today, Gorilla Gold CEO Charles Hughes said, “The Comet Vale Project is rapidly emerging as a camp-scale gold development project, with this resource update incorporating the three new, high-grade discoveries that Gorilla has made within the project area over the past year.”

Hughes added:

This update to the Comet Vale Resource comes hard on the heels of the delivery of a maiden mineral resource for the Vivien Project in April 2025 and an updated resource for Mulwarrie in August 2025, capping off what has been an exceptionally busy year of drilling for the company.

As a result of this upgrade, Gorilla now collectively holds 1.5 million ounces of high-grade gold in Resources across three key projects in prime Goldfields locations in Western Australia.

Looking ahead, Hughes said, “We are now forging ahead with development studies for all three Western Australian projects, while also continuing drilling programs to deliver further Resource growth.”

The post Guess which high-flying ASX All Ords gold share is rocketing again today on a ‘major upgrade’ appeared first on The Motley Fool Australia.

More reading

• Guess which ASX All Ords gold stock is lifting off today on ‘excellent recoveries’

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.